Cargando…

FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway

FLT3-ITD is the most frequent tyrosine kinase mutation in acute myeloid leukemia (AML) associated with poor prognosis. We previously reported that activation of STAT5 confers resistance to PI3K/Akt inhibitors on the FLT3-ITD-positive AML cell line MV4-11 and 32D cells driven by FLT3-ITD (32D/ITD) bu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okada, Keigo, Nogami, Ayako, Ishida, Shinya, Akiyama, Hiroki, Chen, Cheng, Umezawa, Yoshihiro, Miura, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823622/ https://www.ncbi.nlm.nih.gov/pubmed/29507660 http://dx.doi.org/10.18632/oncotarget.22926

Ejemplares similares

Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD–Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway()
por: Nogami, Ayako, et al.
Publicado: (2018)

FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM
por: Watanabe, Daisuke, et al.
Publicado: (2019)

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
por: Nogami, Ayako, et al.
Publicado: (2015)

Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2
por: Ishida, Shinya, et al.
Publicado: (2018)

The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
por: Qiu, Yang, et al.
Publicado: (2023)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
por: Akiyama, Hiroki, et al.
Publicado: (2020)

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
por: Kasper, S, et al.
Publicado: (2012)

Pim-2 kinase inhibits inflammation by suppressing the mTORC1 pathway in atherosclerosis
por: Liao, Minqi, et al.
Publicado: (2021)

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
por: Mali, Raghuveer Singh, et al.
Publicado: (2020)

FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways
por: Wu, Min, et al.
Publicado: (2019)

Characterization of FLT3-ITD(mut) acute myeloid leukemia: molecular profiling of leukemic precursor cells
por: Travaglini, Serena, et al.
Publicado: (2020)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration
por: Grundler, Rebekka, et al.
Publicado: (2009)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
por: Lopez, Sophie, et al.
Publicado: (2016)

Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones
por: Al-Mawali, Adhra, et al.
Publicado: (2016)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci
por: Kelsey, Ilana, et al.
Publicado: (2017)

Pim-2/mTORC1 Pathway Shapes Inflammatory Capacity in Rheumatoid Arthritis Synovial Cells Exposed to Lipid Peroxidations
por: Yin, Geng, et al.
Publicado: (2015)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

Defects in mTORC1 Network and mTORC1-STAT3 Pathway Crosstalk Contributes to Non-inflammatory Hepatocellular Carcinoma
por: Li, Ting, et al.
Publicado: (2020)

RUNX1 cooperates with FLT3-ITD to induce leukemia
por: Behrens, Kira, et al.
Publicado: (2017)

Crosstalk of Hedgehog and mTORC1 Pathways
por: Larsen, Lasse Jonsgaard, et al.
Publicado: (2020)

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
por: Kellner, Fabienne, et al.
Publicado: (2020)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
por: Fang, Douglas D., et al.
Publicado: (2021)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress
por: Doshi, Kshama A., et al.
Publicado: (2016)

Overcoming AC220 resistance of FLT3-ITD by SAR302503
por: Kesarwani, M, et al.
Publicado: (2013)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia
por: Frikha, Rim, et al.
Publicado: (2022)

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo
por: Werzowa, Johannes, et al.
Publicado: (2010)

RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes
por: Weinberg, Mark A.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_371rcsm73btfg57u29p3afd39k